These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37843402)

  • 1. T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.
    Gaykema LH; van Nieuwland RY; Lievers E; Moerkerk WBJ; de Klerk JA; Dumas SJ; Kers J; Zaldumbide A; van den Berg CW; Rabelink TJ
    Stem Cells Transl Med; 2024 Jan; 13(1):69-82. PubMed ID: 37843402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
    Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
    Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of Mesenchymal Stromal Cells with Low Immunogenicity from Human PBMC-Derived β2 Microglobulin Knockout Induced Pluripotent Stem Cells.
    Zha S; Tay JC; Zhu S; Li Z; Du Z; Wang S
    Cell Transplant; 2020; 29():963689720965529. PubMed ID: 33172291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of Monkey Induced Pluripotent Stem Cell-Derived Cartilage Lacking Major Histocompatibility Complex Class I Molecules on the Cell Surface.
    Okutani Y; Abe K; Yamashita A; Morioka M; Matsuda S; Tsumaki N
    Tissue Eng Part A; 2022 Jan; 28(1-2):94-106. PubMed ID: 34182799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
    Thongsin N; Wattanapanitch M
    Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection.
    Shao L; Zhang Y; Pan X; Liu B; Liang C; Zhang Y; Wang Y; Yan B; Xie W; Sun Y; Shen Z; Yu XY; Li Y
    Cell Mol Life Sci; 2020 Mar; 77(5):937-952. PubMed ID: 31312880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
    Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
    J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a baculoviral CRISPR/Cas9 vector system for beta-2-microglobulin knockout in human pluripotent stem cells.
    Xiang Z; Ye Q; Zhao Z; Wang N; Li J; Zou M; Lau CH; Zhu H; Wang S; Ding Y
    Mol Genet Genomics; 2024 Aug; 299(1):74. PubMed ID: 39085666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system.
    Thongsin N; Wattanapanitch M
    Stem Cell Res; 2021 Oct; 56():102551. PubMed ID: 34628247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy.
    Meshitsuka S; Ninomiya R; Nagamura-Inoue T; Okada T; Futami M; Tojo A
    Regen Ther; 2022 Dec; 21():442-452. PubMed ID: 36313397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.
    Tsuneyoshi N; Hosoya T; Takeno Y; Saitoh K; Murai H; Amimoto N; Tatsumi R; Watanabe S; Hasegawa Y; Kikkawa E; Goto K; Nishigaki F; Tamura K; Kimura H
    Stem Cell Res Ther; 2024 Jul; 15(1):193. PubMed ID: 38956724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8
    Matsumoto R; Enzhi Y; Takeda K; Morimoto K; Yogo K; Harada M; Tokushige K; Maehara Y; Hirota S; Kojima Y; Ito M; Sougawa N; Miyagawa S; Sawa Y; Okumura K; Uchida K
    J Heart Lung Transplant; 2024 Aug; 43(8):1348-1357. PubMed ID: 38657776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminished expression of major histocompatibility complex facilitates the use of human induced pluripotent stem cells in monkey.
    Wang X; Lu M; Tian X; Ren Y; Li Y; Xiang M; Chen S
    Stem Cell Res Ther; 2020 Aug; 11(1):334. PubMed ID: 32746912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II.
    Petrus-Reurer S; Winblad N; Kumar P; Gorchs L; Chrobok M; Wagner AK; Bartuma H; Lardner E; Aronsson M; Plaza Reyes Á; André H; Alici E; Kaipe H; Kvanta A; Lanner F
    Stem Cell Reports; 2020 Apr; 14(4):648-662. PubMed ID: 32197113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells.
    Norbnop P; Ingrungruanglert P; Israsena N; Suphapeetiporn K; Shotelersuk V
    Sci Rep; 2020 May; 10(1):8472. PubMed ID: 32439978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
    Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
    Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.
    Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J
    J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing.
    Bogomiakova ME; Sekretova EK; Eremeev AV; Shuvalova LD; Bobrovsky PA; Zerkalenkova EA; Lebedeva OS; Lagarkova MA
    Stem Cell Res; 2021 Aug; 55():102451. PubMed ID: 34237591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a B2M homozygous knockout human somatic cell nuclear transfer-derived embryonic stem cell line using the CRISPR/Cas9 system.
    Lee OH; Lee S; Park M; Moon S; Hwang S; Kim B; Kim CY; Lee DR; Shim SH; Park KH; Chung HM; Choi Y
    Stem Cell Res; 2022 Mar; 59():102643. PubMed ID: 34971932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.